Searchable abstracts of presentations at key conferences on calcified tissues
ISSN 2052-1219 (online)
Bone Abstracts
Menu
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Previous issue
|
Volume 3
|
ECTS2014
|
Next issue
European Calcified Tissue Society Congress 2014
Prague,
Czech Republic
17 May 2014 - 20 May 2014
European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic
Summary
Abstract Book
Programme
Volume Editors
eposters
Abstracts
Oral Posters
Clinical
Table of contents
Next section
Pre-Clinical
A transdermal patch delivering the PTHrP1-34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo
Yates John
Alexandersen Peter
Krogsaa Annesofie
Nedergaard Bettina
Clarkin Marcie
Hattersley Gary
Hansen Kris
Karsdal Morten
Christiansen Claus
ba0003OP1
Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey
Hattersley Gary
Doyle Nancy
Varela Aurore
Guldberg Robert E
Smith Susan Y
ba0003OP2
PTH treatment induces WNT10b expression in humans lymphoid cells
D'Amelio Patrizia
Sassi Francesca
Buondonno Ilaria
Spertino Elena
D'Amico Lucia
Roato Ilaria
Isaia Giovanni Carlo
ba0003OP3
Denosumab treatment in women with osteoporosis reduces hip cortical porosity
Zebaze Roger M
Libanati Cesar
McClung Michael R
Zanchetta Jose R
Kendler David L
Hoiseth Arne
Wang Andrea
Ghasem-Zadeh Ali
Seeman Ego
ba0003OP4
Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment
Ominsky Michael S
Libanati Cesar
Boyce Rogely
Kostenuik Paul J
Baron Roland
Wagman Rachel B
Dempster David W
ba0003OP5
Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass
Thomas Thierry
Cheung Angela M
Shane Elizabeth
Zanchetta Jose R
Kearns Ann
Hans Didier
Lin Celia J F
Austin Matthew
Libanati Cesar
ba0003OP6
In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate
Brown Jacques P
Bolognese Michael A
Ho Pei-Ran
Roux Christian
Bone Henry G
Bonnick Sydney L
van den Bergh Joop
Ferreira Irene
Ghelani Prayashi
Dakin Paula
Wagman Rachel B
Recknor Christopher
ba0003OP7
Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study
Appelman-Dijkstra Natasha
Claessen Kim
Hamdy Neveen
Pereira Alberto
Biermasz Nienke
ba0003OP8
Zoledronate prevents lactation induced loss of bone strength and micro-architecture
Wendelboe Mette Hoegh
Thomsen Jesper Skovhus
Bruel Annemarie
ba0003OP9
Zoledronate reverses bone marrow adiposity in disuse osteopenic rats
Jensen Michael Vinkel
Bruel Annemarie
Thomsen Jesper Skovhus
ba0003OP10
A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia
Carpenter Thomas
Imel Erik
Ruppe Mary
Weber Thomas
Klausner Mark
Wooddell Margaret
Kawakami Tetsuyoshi
Ito Takahiro
Zhang Xiaoping
Humphrey Jeffrey
Insogna Karl
Peacock Munro
ba0003OP11
Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia
Zhang Xiaoping
Carpenter Thomas
Imel Erik
Ruppe Mary
Weber Thomas
Klausner Mark
Kawakami Tetsuyoshi
Ito Takahiro
Humphrey Jeffrey
Insogna Karl
Peacock Munro
ba0003OP12
Decrease in expression of MMP3 in osteoblast protects against bone loss
Zarka-Prost-Dumont Mylene
Jehan Frederic
Ostertag Agnes
de Vernejoul Marie-Christine
Geoffroy Valerie
ba0003OP13
Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study
Hassler Norbert
Gamsjaeger Sonja
Hofstetter Birgit
Brozek Wolfgang
Misof Barbara
Roschger Paul
Klaushofer Klaus
Paschalis Eleftherios
ba0003OP14
Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study
Hawley Sam
Wallace Gemma
Javaid M Kassim
Rubin Katrine
Judge Andrew
Vestergaard Peter
Eastell Richard
Diez-Perez Adolfo
Arden Nigel K
Cooper Cyrus
Prieto-Alhambra Daniel
Abrahamsen Bo
ba0003OP15
The impact of common comorbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study
Reyes Carlen
Nogues Xavier
Cooper Cyrus
Diez-Perez Adolfo
Prieto-Alhambra Daniel
ba0003OP16
Dynamic changes in bone marrow adiposity during the menstrual cycle
Veldhuis-Vlug Annegreet
Limonard Eelkje
van Dussen Laura
Runge Jurgen
Tanck Michael
Endert Erik
Heijboer Annemieke
Fliers Eric
Hollak Carla
Akkerman Erik
Bisschop Peter
ba0003OP17
Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?
Evans Amy
Eastell Richard
Walsh Jennifer
ba0003OP18
Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials
Bilezikian John P
Maruani Gerard
Rothman Jeffrey
Clarke Bart L
Mannstadt Michael
Vokes Tamara
Lagast Hjalmar
Shoback Dolores M
ba0003OP19
No beneficial effects of vitamin D supplementation in muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial.
Rolighed Lars
Rejnmark Lars
Sikjaer Tanja
Heickendorff Lene
Vestergaard Peter
Mosekilde Leif
Christiansen Peer
ba0003OP20